Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients
Status:
Completed
Trial end date:
2016-01-27
Target enrollment:
Participant gender:
Summary
This is a randomized, vehicle controlled, active comparator, parallel group, study with a
total duration of 24 weeks including screening and follow-up. Study drug is applied topically
for 2 cycles of 4 week treatment, separated by 4 weeks off-treatment. Assessors of study
endpoints are blinded to treatment allocation.